Axon and Axogen Report Strong Growth in 2024

Axon Enterprise, Inc. reported a 33% increase in revenue to $2.1 billion for 2024, marking its third consecutive year of over 30% annual growth, with Q4 revenue reaching $575 million, up 34% year over year. The company projects 2025 revenue guidance between $2.55 billion and $2.65 billion, maintaining a projected 25% growth rate, driven by its TASER and body camera sales and expansion of AI-powered public safety solutions. Meanwhile, Axogen, Inc. achieved a 17.8% revenue growth and a Q4 net income of $0.4 million, marking a significant turnaround from a net loss the previous year. Axogen, focusing on peripheral nerve repair, is preparing for an upcoming investor day to discuss strategic plans and expects FDA approval for its surgical solutions. Both companies demonstrate significant advancements, with Axon's continued growth in public safety technology and Axogen's progress in healthcare solutions for nerve injuries.